Frédéric Miege

Title: Frédéric Miege: Innovator in Medicinal Chemistry

Introduction

Frédéric Miege is a notable inventor based in Lyons, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target various neurological and metabolic disorders. His work is characterized by a focus on innovative solutions for complex health issues.

Latest Patents

Frédéric Miege holds a patent for "Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4." This invention relates to a compound of formula (I) that includes various alkyl and cycloalkyl groups, which can be used as a medicament. The patent outlines the compound's potential applications in treating cognitive deficits associated with conditions such as Down syndrome, Alzheimer's disease, and several types of cancer. The compound also has implications for regulating body temperature and addressing neuroinflammation.

Career Highlights

Miege is currently associated with Perha Pharmaceuticals, where he continues to advance his research and development efforts. His work has led to the creation of innovative compounds that hold promise for treating a range of serious health conditions. His dedication to medicinal chemistry has positioned him as a key figure in the industry.

Collaborations

Frédéric Miege has collaborated with notable colleagues, including Emmanuel Deau and Pascal George. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of their collective research efforts.

Conclusion

Frédéric Miege's contributions to medicinal chemistry through his innovative patents and collaborations highlight his commitment to addressing significant health challenges. His work continues to inspire advancements in the treatment of various diseases.